二次谐波/双光子激发荧光显微成像技术定量评估非酒精性脂肪性肝病小鼠模型肝纤维化的价值

王晓晓; 赵洁; 李晓鹤; 饶慧瑛; 魏来; 刘峰

doi:10.3969/j.issn.1001-5256.2019.08.027

二次谐波/双光子激发荧光显微成像技术定量评估非酒精性脂肪性肝病小鼠模型肝纤维化的价值

DOI: 10.3969/j.issn.1001-5256.2019.08.027

1 北京大学人民医院，北京大学肝病研究所，丙型肝炎和肝病免疫治疗北京市重点实验室
2 北京大学人民医院检验科
3 清华大学附属北京长庚医院肝胆胰中心

基金项目:

“重大新药创制”科技重大专项(2018ZX09201002-001-005)；政府间国际科技创新合作重点专项(中国与新加坡双边合作项目)(2016YFE0116800)；北京大学人民医院研究与发展基金(RDX2018-06)；

详细信息

中图分类号: R575;R-332
计量
- 文章访问数: 1566
- HTML全文浏览量: 69
- PDF下载量: 318
- 被引次数: 1
出版历程
- 收稿日期: 2019-04-17
- 出版日期: 2019-08-20

Value of second harmonic generation/two-photon excitation fluorescence in quantitative evaluation of liver fibrosis in mice with nonalcoholic fatty liver disease

People’s Hospital, Peking University; Peking University Hepatology Institute; Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases

Research funding:

摘要

摘要:
目的通过二次谐波(SHG)和双光子激发荧光(TPEF)显微成像技术分析非酒精性脂肪性肝病(NAFLD)小鼠模型胶原参数动态变化,找出并建立适合蛋氨酸胆碱缺乏饲料(MCD)诱导的NAFLD小鼠的自动化定量评估参数,为SHG/TPEF显微成像技术应用于临床提供实验依据。方法获取MCD饮食小鼠不同时间点(0、4、8、12、16、20和24周)的肝组织标本,行HE、Masson和天狼猩红(SR)染色,并计算胶原蛋白比例面积(CPA)和羟脯氨酸(HYP)。使用SHG/TPEF纤维成像技术分析100个胶原参数。以造模后不同时间点和不同纤维化分期(S0～S4)为标准,采用支持向量机算法(SVM)模型分析胶原参数,并对参数行受试者工作特征曲线(ROC曲线)分析,同时与CPA、HYP进行比较。结果在MCD小鼠模型中,HE和SR染色后可以观察到随着造模时间的延长,肝小叶内脂肪变形成,纤维化逐渐加重。分别基于造模不同时间点和不同肝纤维化分期,选出26和27个参数;进一步采用SVM模型分析筛选出7个共同参数(#StrCV、#ShortStrCV、#ThickStrCV、#StrPTAgg、#StrPSAgg、...
- 非酒精性脂肪性肝病 /
- 肝硬化 /
- 显微成像技术 /
- 小鼠,近交C57BL
Abstract:
Objective To investigate the dynamic changes in collagen parameters in mice with nonalcoholic fatty liver disease (NAFLD) by second harmonic generation (SHG) /two-photon excitation fluorescence (TPEF) , to establish the parameters for automatic quantitative evaluation of mice with NAFLD induced by methionine-and choline-deficient diet (MCD) , and to provide an experimental basis for the application of SHG/TPEF in clinical practice. Methods Liver tissue specimens of MCD mice were collected at weeks 0, 4, 8, 12, 16, 20, and 24, and HE staining, Masson staining, and sirius red (SR) staining were performed. Collagen proportionate area (CPA) and hydroxyproline (HYP) were calculated. SHG/TPEF was used to analyze 100 collagen parameters. With time points and fibrosis stage (S0-S4) as criteria, the SVM model was used to analyze the collagen parameters. A receiver operating characteristic (ROC) curve analysis was performed for the collagen parameters, and these parameters were compared with CPA and HYP in terms of the area under the ROC curve (AUC) . Results In the MCD mice, HE and SR staining showed that over the time of modeling, hepatic steatosis was observed in hepatic lobules, with gradual aggravation of fibrosis. A total of 26 parameters were screened out based on their correlation with time point, and 27 parameters were screened out based on their correlation with liver fibrosis stage. The analysis based on the SVM model identified 7 shared parameters (#StrCV, #ShortStrCV, #ThickStrCV, #StrPTAgg, #StrPSAgg, #LongStrPSAgg, and StrLengthPSAgg) . These 7 parameters had anAUC of 0. 857-0. 923 (P < 0. 05) in predicting different stages of liver fibrosis and an AUC of 0. 823-0. 976 (P < 0. 05) in predicting liver fibrosis at different time points. These 7 parameters were compared with CPA and HYP in terms of their value in predicting liver fibrosis, and it was found that the 7 parameters had a similar AUC as CPA and HYP in predicting S0 fibrosis, while the 7 parameters had a significantly higher AUC than CPA and HYP in predicting S1-S4 fibrosis. The 7 parameters had a similar AUC as CPA and HYP at week 0 of modeling, while at week 4 of modeling, the 7 parameters had a significantly higher AUC than CPA and HYP. Conclusion Seven parameters associated with fibrosis stage and time point can accurately reflect the changes in liver fibrosis in different stages and at different time points in a model of MCD-induced NAFLD, and therefore, they can be used for specific and accurate monitoring of liver fibrosis in a quantitative manner in this model.
- non-alcoholic fatty liver disease /
- liver cirrhosis /
- excitation fluorescence imaging /
- mice, inbred C57BL

HTML全文

参考文献(18)

[1] YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH:Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15 (1) :11-20.

[2] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol, 2018, 34 (12) :2515-2519. (in Chinese) 李婕.亚洲地区非酒精性脂肪性肝病的流行病学特点[J].临床肝胆病杂志, 2018, 34 (12) :2515-2519.

[3] LI XH, WEI L. Heterogeneity and homogeneity of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2018, 34 (12) :2491-2494. (in Chinese) 李晓鹤, 魏来.非酒精性脂肪性肝病的同质性和异质性[J].临床肝胆病杂志, 2018, 34 (12) :2491-2494.

[4] ADAMS LA, ANSTEE QM, TILG H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J]. Gut, 2017, 66 (6) :1138-1153.

[5] DULAI PS, SINGH S, PATEL J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:Systematic review and meta-analysis[J]. Hepatology, 2017, 65 (5) :1557-1565.

[6] ANGULO P, KLEINER DE, DAM-LARSEN S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2015, 149 (2) :389-397.

[7] EKSTEDT M, HAGSTRM H, NASR P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J]. Hepatology, 2015, 61 (5) :1547-1554.

[8] CHEN YZ, CHEN CL, TIAN X, et al. Research advances in animal models based on the pathogenesis and treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2017, 33 (12) :2457-2461. (in Chinese) 陈艳珍, 陈成良, 田兴, 等.基于非酒精性脂肪性肝病机制及治疗的动物模型研究进展[J].临床肝胆病杂志, 2017, 33 (12) :2457-2461.

[9] SUN W, CHANG S, TAI DC, et al. Nonlinear optical microscopy:Use of second harmonic generation and two-photon microscopy for automated quantitative liver fibrosis studies[J]. J Biomed Opt, 2008, 13 (6) :064010.

[10] XU S, WANG Y, TAI DC, et al. qFibrosis:A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J]. J Hepatol, 2014, 61 (2) :260-269.

[11] WANG TH, CHEN TC, TENG X, et al. Automated biphasic morphological assessment of hepatitis B-related liver fibrosis using second harmonic generation microscopy[J]. Sci Rep, 2015, 5:12962.

[12] SUN Y, ZHOU J, WU X, et al. Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak “stable”patients on anti-HBV therapy[J]. Sci Rep, 2018, 8 (1) :2989.

[13] WANG Y, VINCENT R, YANG J, et al. Dual-photon microscopy-based quantitation of fibrosis-related parameters (qFP) to model disease progression in steatohepatitis[J]. Hepatology, 2017, 65 (6) :1891-1903.

[14] LIU F, ZHAO JM, RAO HY, et al. Second harmonic generation reveals subtle fibrosis differences in adult and pediatric nonalcoholic fatty liver disease[J]. Am J Clin Pathol, 2017, 148 (6) :502-512.

[15] LIU F, CHEN L, RAO HY, et al. Automated evaluation of liver fibrosis in thioacetamide, carbon tetrachloride, and bile duct ligation rodent models using second-harmonic generation/two-photon excited fluorescence microscopy[J]. Lab Invest, 2017, 97 (1) :84-92.

[16] ZHENG YJ, WANG Y. Histological assessment of reversal of liver fibrosis and cirrhosis[J]. J Clin Hepatol, 2019, 35 (4) :709-713. (in Chinese) 郑永见, 汪艳.肝纤维化和肝硬化逆转的组织学评价[J].临床肝胆病杂志, 2019, 35 (4) :709-713.

[17] KLEINER DE, BRUNT EM, VAN NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41 (6) :1313-1321.

[18] JULURI R, VUPPALANCHI R, OLSON J, et al. Generalizability of the nonalcoholic steatohepatitis clinical research network histologic scoring system for nonalcoholic fatty liver disease[J]. J Clin Gastroenterol, 2011, 45 (1) :55-58.

施引文献